type 1 diabetes – Medxy AI

Dapagliflozin’s Effects on Hormonal Regulation and Ketone Production in Adults with Type 1 Diabetes: Insights from a Randomised Controlled Crossover Trial

By MedXY 09/17/2025

This trial evaluates dapagliflozin's impact on key hormones and ketogenesis in type 1 diabetes, demonstrating increased ketone bodies without altering GLP-1, glucagon, or somatostatin secretion, highlighting risks and benefits for adjunct therapy.

Clinical Updates Wellness & Lifestyle

Advancing Type 1 Diabetes Care: Stem Cell-Derived Islet Therapy with Zimislecel

By MedXY 09/10/2025

Zimislecel, an allogeneic stem cell-derived islet-cell therapy, demonstrates promising safety and efficacy for type 1 diabetes, restoring physiologic islet function and enabling insulin independence in a phase 1-2 trial.

Clinical Updates Wellness & Lifestyle

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial

By MedXY 08/24/2025

The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.

Clinical Updates Wellness & Lifestyle

Adjunct-to-Insulin Therapy Using SGLT2 Inhibitors in Youth with Type 1 Diabetes: Clinical Impact and Renal Outcomes

By MedXY 08/21/2025

SGLT2 inhibitors adjunct to insulin improve glycemic control, reduce hyperfiltration, and are generally safe in youth with type 1 diabetes under careful ketone monitoring and DKA risk mitigation.

Clinical Updates Wellness & Lifestyle

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

By MedXY 08/05/2025

Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.

Clinical Updates Wellness & Lifestyle

Automated Insulin Delivery in Young Children with Type 1 Diabetes: Insights from the LENNY Trial

By MedXY 08/02/2025

The LENNY trial demonstrates that the MiniMed 780G automated insulin delivery system improves glycaemic control and maintains safety in children aged 2–6 years with type 1 diabetes.

Wellness & Lifestyle

Maternal Diet and Childhood Diabetes: Unveiling the Link

By MedXY 07/29/2025

A large Danish study reveals that pro-inflammatory diets during pregnancy may increase the risk of type 1 diabetes in offspring, emphasizing the importance of maternal nutrition.